8-K: Lantern Pharma Reports 2025 Results, Advances AI & Clinical Pipeline

Lantern Pharma announced its Q4 and full-year 2025 financial results, highlighting clinical validation across multiple oncology programs and the commercialization progress of its AI platforms.

Summary

• Full-year 2025 net loss reduced by 18% to approximately $17.1 million ($1.57 per share) from approximately $20.8 million ($1.93 per share) in 2024.
• Cash, cash equivalents, and marketable securities were approximately $10.1 million as of December 31, 2025, a decrease from approximately $24.0 million as of December 31, 2024.
• Existing funds are expected to enable funding of anticipated operating expenses and capital expenditure requirements until at least approximately late July 2026 to mid-September 2026, with substantial additional funding needed in the near future.
• LP-300 Phase 2 HARMONIC trial continues enrollment and patient follow-up across the United States, Japan, and Taiwan, with targeted enrollment in Japan completed ahead of schedule in July 2025.
• A Type C meeting package was submitted to the FDA in March 2026, with a meeting scheduled for mid-May 2026, seeking feedback on proposed protocol amendments for LP-300, including focusing enrollment on EGFR exon 21 L858R patients and updating the dosing schedule to allow for up to 8 cycles of treatment.
• LP-184 Phase 1a trial achieved all primary endpoints with a 48% clinical benefit rate at or above the therapeutic dose threshold, demonstrating durable disease control in heavily pre-treated advanced cancer patients.
• Biomarker-guided Phase 1b/2 trials for LP-184 are planned in TNBC, NSCLC with KEAP1/STK11 mutations, and an investigator-led clinical study in Denmark in PTGR1 overexpressing bladder cancers, all subject to additional funding.
• Starlight Therapeutics received FDA IND clearance for a planned Phase 1 pediatric CNS cancer trial of STAR-001 (LP-184) in Atypical Teratoid Rhabdoid Tumor (ATRT) and other rare pediatric cancers.
• STAR-001 has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA for ATRT, hepatoblastoma, rhabdomyosarcoma, and malignant rhabdoid tumors, potentially qualifying for FDA Priority Review Vouchers (PRVs) valued at $100 million to $150 million or more.
• LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas, adding to existing designations for mantle cell lymphoma and high-grade B-cell lymphomas, and showed a complete metabolic response in a therapeutically exhausted DLBCL patient.
• The RADR AI Platform is undergoing global expansion with the initiation of an AI Center of Excellence in India to industrialize the platform and accelerate global biopharma development opportunities.
• withZeta.ai, a first-of-its-kind multi-agentic AI co-scientist platform designed to accelerate drug development insights across more than 438 rare cancers, was introduced in late 2025 and is in active demo and beta testing with over 25 biotech companies, representing a significant near-term commercialization opportunity.
• Total operating expenses for the full year 2025 were approximately $17.98 million, a 19% reduction year-over-year from approximately $22.22 million in 2024, primarily due to a 29% decrease in R&D expenses to approximately $11.5 million.
• The company addressed a false online article stating the CEO was stepping down, confirming Panna Sharma continues to serve as President and Chief Executive Officer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While clinical and AI platform progress is notable and positive, the significant reduction in cash and the explicit need for substantial near-term funding introduce considerable financial uncertainty and risk.

Positives

• Net loss reduced by 18% year-over-year to approximately $17.1 million in 2025.
• Total operating expenses decreased by 19% year-over-year, with R&D expenses down 29% to approximately $11.5 million in 2025.
• LP-300 Phase 2 HARMONIC trial completed targeted enrollment in Japan ahead of schedule in July 2025.
• LP-300 safety lead-in cohort demonstrated an 86% clinical benefit rate and 43% objective response rate, including one durable complete response.
• LP-184 Phase 1a achieved all primary endpoints with a 48% clinical benefit rate at or above the therapeutic dose threshold and established a recommended Phase 2 Dose (RP2D) of 0.39mg/kg with a favorable safety profile.
• Starlight Therapeutics received FDA IND clearance for STAR-001 (LP-184) in pediatric CNS cancers.
• STAR-001 has multiple Rare Pediatric Disease and Orphan Drug Designations, potentially qualifying for valuable FDA Priority Review Vouchers (PRVs) upon approval.
• LP-284 received FDA Orphan Drug Designation for soft tissue sarcomas and showed a confirmed complete metabolic response in a heavily pretreated DLBCL patient.
• Introduction of withZeta.ai, a multi-agentic AI co-scientist platform, which is in active beta testing with over 25 biotech companies and represents a near-term commercialization opportunity.
• Initiation of an AI Center of Excellence in India to industrialize the RADR platform and accelerate global biopharma development.
• CEO Panna Sharma's continued leadership was confirmed, refuting false online reports.

Negatives

• Cash, cash equivalents, and marketable securities decreased significantly from approximately $24.0 million at December 31, 2024, to approximately $10.1 million at December 31, 2025.
• Existing funds are projected to last only until late July 2026 to mid-September 2026, requiring substantial additional funding in the near future.
• Planned LP-184 Phase 1b/2 trials and Starlight Therapeutics' pediatric CNS cancer trial initiation are explicitly stated as subject to additional funding.
• The company sold 356,922 shares under an ATM Sales Agreement for gross proceeds of $1,624,547 during 2025, indicating ongoing dilution.

Risks

• There is no assurance that the FDA will concur with the proposed amendments to the LP-300 HARMONIC study protocol.
• The company may not be able to secure sufficient future funding when needed to advance and support its existing and planned clinical trials and operations.
• Observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies, and development will be consistent or successful.
• The research conducted by the company and its collaborators may not be successful.
• The company may not be successful in licensing potential candidates or in completing potential partnerships and collaborations.
• None of the company's product candidates have received FDA marketing approval, and there is a risk that the company may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for its product candidates.
• No drug product based on the proprietary RADR AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product.
• The AI platform commercialization efforts, including withZeta.ai, may not generate the anticipated revenue or achieve the expected market adoption.
• The company's forward-looking statements may not prove to be accurate, or any other results or events projected or contemplated by its forward-looking statements may not in fact occur.

Future Outlook

The company plans a Type C meeting with the FDA in mid-May 2026 for LP-300 protocol amendments, expects additional HARMONIC trial data readouts and potential partnership announcements in 2026, and aims to initiate LP-184 Phase 1b/2 trials and a pediatric CNS cancer trial through Starlight Therapeutics in H1 2026, all subject to additional funding. Commercial efforts for the RADR AI and withZeta.ai platforms will scale up in 2026, with a focus on converting beta engagements to commercial partnerships and pursuing additional funding, including grants.

Management Comments

• "2025 was a defining year for Lantern Pharma as we achieved clinical validation across multiple programs while establishing the foundation for our next phase of growth."
• "The encouraging and developing LP-300 Phase 2 HARMONIC observations, combined with successful Phase 1a completion for LP-184 and FDA IND clearance for our pediatric CNS cancer program through Starlight Therapeutics, represent transformational milestones that validate and strengthen our AI-driven approach to precision oncology."
• "Our full-year results reflect disciplined execution with a 19% reduction in total operating expenses year-over-year, even as we advanced multiple clinical programs through key inflection points and introduced a highly unique multi-agentic system aimed at conquering rare cancers."
• "As we move into 2026, we are positioning to advance multiple high-value clinical programs, expand our RADR platforms commercial reach and revenue potential globally through our new AI Center of Excellence in India and strengthen our balance sheet."
• "On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.5 million per program."
• "2026 can be a critical year for the commercialization of our AI platforms to support broad-based drug development and scientific productivity in R&D."
• "We are building for a future where AI co-scientists are commonplace in knowledge work across the pharmaceutical and biotech industries – augmenting human expertise, accelerating discovery timelines, and dramatically improving the economics of drug development."
• "We believe this represents a potential near-term market opportunity of $20 to $50 billion, and withZeta.ai is our first agentic-based commercial product designed to capture a meaningful share of that market."

Industry Context

StockSavvy.ai notes that Lantern Pharma's focus on AI-driven drug discovery and development, particularly for rare cancers and difficult-to-treat indications like never-smoker NSCLC and TNBC, aligns with a broader industry trend towards precision oncology and leveraging advanced computational methods to de-risk and accelerate R&D. The commercialization of AI platforms like withZeta.ai positions Lantern to capitalize on the growing market for AI-as-a-service in biopharma, a strategy also pursued by companies like BenevolentAI and Exscientia, aiming to reduce the high costs and long timelines traditionally associated with drug development. The pursuit of Priority Review Vouchers for rare pediatric diseases is a recognized strategy for non-dilutive value creation, seen across the biotech sector.

Comparison to Industry Standards

• The company states its newly developed drug programs advance from AI insights to first-in-human clinical trials in 2-3 years at approximately $1.0-2.5 million per program, which is significantly faster and more cost-effective than the industry average of 10-15 years and over $2 billion for a new drug.
• The estimated $4+ billion annual market opportunity for never-smoker NSCLC, with no specifically approved therapies, highlights a significant unmet need compared to other lung cancer segments with established treatments.
• The potential value of FDA Priority Review Vouchers (PRVs) at $100 million to $150 million or more is consistent with recent market transactions for such vouchers, providing a clear benchmark for this non-dilutive asset.
• The global rare disease therapeutics market projected to exceed $300 billion by 2028, and the broader pharmaceutical R&D outsourcing and AI-enabled drug discovery market, provide a large addressable market for withZeta.ai, comparable to the strategic positioning of other AI drug discovery firms.

Management Changes

Stakeholder Impact

• Shareholders: Potential for significant dilution due to the need for additional funding; potential long-term value creation from clinical pipeline and AI platform commercialization; potential non-dilutive value from Priority Review Vouchers.
• Patients: Continued progress in developing therapies for difficult-to-treat cancers (NSCLC, TNBC, pediatric CNS cancers, lymphomas, sarcomas).
• Employees: Expansion with an AI Center of Excellence in India suggests growth opportunities.
• Partners/Collaborators: Opportunities for collaboration on LP-300 and commercialization of AI platforms.
• Creditors: The need for substantial additional funding could impact credit risk perception.

Next Steps

• Mid-May 2026: Type C meeting with FDA to discuss proposed HARMONIC protocol amendments.
• 2026: Planned Investigator Sponsored Trial evaluating LP-300 in combination with standard-of-care agents in frontline NSCLC patients with specific driver mutations.
• H1 2026: Planned initiation of LP-184 Phase 1b/2 trials in TNBC and NSCLC (subject to funding).
• H1 2026: Investigator-led clinical study initiation in Denmark in PTGR1 overexpressing bladder cancers with DNA damage repair mutations.
• 2026: Planned pediatric CNS cancer trial initiation through Starlight Therapeutics (subject to funding).
• 2026: Additional HARMONIC trial data readouts and potential partnership announcements.
• 2026: Scale-up of RADR AI and withZeta.ai platform commercial efforts through India AI Center of Excellence.
• 2026: Continued commercialization of the withZeta.ai multi-agentic co-scientist platform, including conversion of beta engagements to commercial partnerships and expansion across the rare cancer research community through a subscription-based service.
• 2026: Pursuit of additional funding, including potential grant revenue, to fund planned operations and clinical advancement.

Key Dates

Recommendation

The company shows promising clinical progress and strategic advancements in its AI platforms, which could drive long-term value. However, the significant decline in cash reserves and the explicit need for substantial additional funding in the near future introduce considerable financial uncertainty and potential for dilution. This creates a balanced risk-reward profile, suggesting a "hold" recommendation until there is more clarity on the funding strategy and its impact.

Keywords

oncology, biopharmaceutical, AI, machine learning, RADR platform, withZeta.ai, cancer drug development, clinical trials, LP-300, NSCLC, LP-184, TNBC, pediatric CNS cancer, STAR-001, ATRT, Orphan Drug Designation, Priority Review Voucher, LP-284, soft tissue sarcoma, DLBCL, financial results, biotech, pharmaceutical, precision oncology, rare cancers, FDA IND clearance, EGFR mutation